1. Home
  2. BRO vs GMAB Comparison

BRO vs GMAB Comparison

Compare BRO & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brown & Brown Inc.

BRO

Brown & Brown Inc.

N/A

Current Price

$68.19

Market Cap

24.2B

Sector

Finance

ML Signal

N/A

GMAB

Genmab A/S ADS

N/A

Current Price

$33.55

Market Cap

20.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BRO
GMAB
Founded
1939
1999
Country
United States
Denmark
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.2B
20.3B
IPO Year
1994
2008

Fundamental Metrics

Financial Performance
Metric
BRO
GMAB
Price
$68.19
$33.55
Analyst Decision
Hold
Strong Buy
Analyst Count
15
8
Target Price
$82.07
$39.56
AVG Volume (30 Days)
1.6M
2.5M
Earning Date
04-27-2026
05-07-2026
Dividend Yield
1.07%
N/A
EPS Growth
N/A
N/A
EPS
1.90
N/A
Revenue
$5,902,000,000.00
N/A
Revenue This Year
$25.61
$17.85
Revenue Next Year
$6.85
$16.04
P/E Ratio
$35.88
$1.90
Revenue Growth
22.83
N/A
52 Week Low
$53.81
$23.62
52 Week High
$96.55
$35.43

Technical Indicators

Market Signals
Indicator
BRO
GMAB
Relative Strength Index (RSI) 38.43 59.15
Support Level $64.60 $32.54
Resistance Level $70.12 $34.37
Average True Range (ATR) 1.47 0.60
MACD -0.67 -0.17
Stochastic Oscillator 3.25 42.92

Price Performance

Historical Comparison
BRO
GMAB

About BRO Brown & Brown Inc.

Brown & Brown Inc is a diversified insurance agency, wholesale brokerage, insurance programs, and service. The company's business is divided into two reportable segments: (i) the Retail segment, and (ii) the Specialty Distribution segment. The Retail segment provides a broad range of insurance products and services to commercial, public and quasi-public entities, and to professional and individual customers, as well as non-insurance warranty services and products through automobile and recreational vehicle dealer services businesses. The Specialty Distribution segment consists of wholesale brokerage and specialty businesses. Its geographic area is U.S, U.K and Others.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: